Review: Hypertension in diabetes: a perspective from clinical pharmacology

Abstract

The treatment of co-existing hypertension is vital to reduce morbidity and mortality from complications of diabetes. There is a vast array of evidence on the subject and the choice of antihypertensive medication is extensive. We have reviewed the evidence for blood pressure (BP) control in diabetes, and examined the evidence to support the use of each class of drug, concentrating on patients without nephropathy or microalbuminuria. Control of BP should be the overriding aim, and requires over time more than one drug in most patients. The weight of evidence suggests that BP-lowering per se is more important than the actual agent used.

Keywords

diabetes hypertension antihypertensive therapy clinical trials.

Get full access to this article

View all access options for this article.

References

MacLeod MJ , McLay J. Drug treatment of hypertension complicating diabetes mellitus. Drugs 1998;56:189-202.

Estacio RO , Schrier RW Antihypertensive therapy in type 2 diabetes: Implications of the Appropriate Blood pressure Control in Diabetes (ABCD) Trial. Am J Cardiol 1998;82:9R-14R.

SIGN guideline 55: Management of Diabetes ( www.sign.ac.uk).

Ramsay LE , Williams B. , Johnston GD et al. Guidelines for management of hypertension: report of the third working party of the British Hypertension Society. J Hum Hypertens 1999;13:569-92.

Chobanian AV , Bakris GL , Black HR The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure . JAMA 2003;289:2560-72.

American Diabetes Association. Treatment of Hypertension in Adults with Diabetes. Diabetes Care 2003;26(suppl 1):S80-S82.

UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-12.

UK Prospective Diabetes Study Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.

Hansson L. , Zanchetti A. , Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998 ;351:1755-62.

10.

Tuomilehto J. , Rastenyte D. , Birkenhager WH et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med 1999;340:677-84.

11.

SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991;265:3255-64.

12.

ADVANCE Management Committee. ADVANCE: action in diabetes and vascular disease. Preterax and diamicron MR controlled evaluation. Study design and rationale. Diabetologia 2001;44:1118-20.

13.

Harper R. , Ennis CN , Heaney AP et al. A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM. Diabetologia 1995;38:853-9.

14.

Hansson L. , Lindholm LH , Niskanen L. et al. Effect of angiotensin-converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999;353:611-16.

15.

The ALLHAT Officers and Coordinators for the ALLHAT collaborative research group. Major outcomes in high-risk hypertensive patients randomised to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288: 2981-97.

16.

The ALLHAT Officers and Coordinators for the ALLHAT collaborative research group. Major cardiovascular events in hypertensive patients randomised to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2000;283:1967-75.

17.

White WB , Prisant LM , Wright JT Management of patients with hypertension and diabetes: Advances in the evidence for intensive treatment. Am J Med 2000;108:238-45.

18.

UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 39). BMJ 1998;317:713-19.

19.

Estacio RO , Jeffers BW , Hiatt WR et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin dependent diabetes and hypertension . N Engl J Med 1998;338: 645-52.

20.

Tatti P. , Pahor M. , Byington RP et al. Outcome results of the Fosinopril versus Amlodipine cardiovascular events randomised trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998;21:597-603.

21.

Lindholm LH , Hansson L. , Ekbom T. et al. Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: Results from the Swedish Trial in Old Patients with Hypertension - 2. J Hypertens 2000;18:1671-5.

22.

Lindholm LH , Hansson L. , Ekbom T. et al. Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish Trial in Old Partients with hypertension-2. J Hypertens 2000;18:1671-5.

23.

Staessen JA , Wang J. , Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 2001;358:1305-15.

24.

Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-9.

25.

Sleight P. , Yusuf S. , Pogue J. et al. Blood-pressure reduction and cardiovascular risk in HOPE study . Lancet 2001;358:2130-1.

26.

Svensson P. , De Faire U. , Sleight P. , Yusuf S. , Ostergren J. Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE substudy. Hypertension 2001;38:e28-e32.

27.

Kurtz TW

False claims of blood pressure-independent protection by blockade of the renin angiotensin aldosterone system?

Hypertension 2003;41:193-6.

28.

29.

Niskanen L. , Hedner T. , Hansson L. et al. Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker-based treatment regimen: a subanalysis of the captopril prevention project. Diabetes Care 2001;24:2091-6.

30.

PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-41.

31.

Dahlöf B. , Devereux RB , Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.

32.

Lindholm LH , Ibsen H. , Dahlof B. et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:1004-10.

33.

Brown MJ , Cruickshank JK , Dominiczak AF et al. Better blood pressure control: how to combine drugs. J Hum Hypertens 2003;17(2):81-6.